Rituximab
Identification
- Name
- Rituximab
- Accession Number
- DB00073
- Description
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Structure
- Protein Chemical Formula
- C6416H9874N1688O1987S44
- Protein Average Weight
- 143859.7 Da
- Sequences
>Rituximab heavy chain chimeric QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSY NQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVS AASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>Rituximab light chain chimeric QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVR FSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Download FASTA FormatReferences:
- Rituximab - CAS 174722-31-7 [Link]
- Synonyms
- Rituximab
- rituximab-abbs
- rituximab-arrx
- rituximab-pvvr
- External IDs
- GP2013
- IDEC-102
- IDEC-C2B8
- PF 05280586
- PF-05280586
- RG-105
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
Rituximab is indicated in the following conditions Label:
Non–Hodgkin’s Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
Moderate to severe Pemphigus Vulgaris (PV) in adult patients
The biosimilar (approved in November 2018), Truxima, is indicated For the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy 7.
In September 2019, the rituximab injection was approved along with glucocorticoids to manage granulomatosis with polyangiitis (GPA) in addition to microscopic polyangiitis (MPA) in children of at least 2 years of age 9.
- Associated Conditions
- Chronic Lymphocytic Leukaemia (CLL)
- Granulomatosis With Polyangiitis
- Granulomatosis With Polyangiitis (GPA)
- Microscopic Polyangiitis
- Microscopic Polyangiitis (MPA)
- Non-Hodgkin's Lymphoma (NHL)
- Pemphigus Vulgaris (PV)
- Moderate Rheumatoid arthritis
- Moderate to severe pemphigus vulgaris
- Severe Rheumatoid arthritis
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
Rituximab binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin's lymphomas 1. The antibody leads to selective killing of B-cells. The following are the pharmacodynamic outcomes for various conditions, including non- Hodgkin's Lymphoma Label:
Non-Hodgkin’s Lymphoma (NHL) In Non-Hodgkin's Lymphoma patients, the administration of rituximab led to the depletion of circulating and tissue-based B cells. Among 166 patients in Study 1, circulating CD19-positive B cells were depleted within the first three weeks, showing sustained depletion for up to 6-9 months post-treatment in 83% of treated patients. B-cell recovery began at approximately 6 months and median B-cell levels returned to normal by 12 months following the completion of treatment Label. There were sustained and statistically significant decreases in serum IgM and IgG levels measured from 5-11 months following rituximab administration; 14% of patients showed IgM and/or IgG serum levels below the normal range Label.
Rheumatoid Arthritis In rheumatoid arthritis (RA) patients, treatment with rituximab induced the depletion of peripheral B lymphocytes, with the majority of patients showing near-complete depletion (CD19 counts below the lower limit of quantification, 20 c-lls/μl) within 2 weeks after the first dose of rituximab. The majority of treated patients showed peripheral B-cell depletion, sustained for a minimum of 6 months. A small percentage of patients (~4%) had peripheral B-cell depletion that was sustained for more than 3 years after one course of treatment. Total serum immunoglobulin levels, IgM, IgG, and IgA were decreased at 6 months with the greatest change observed in IgM. At Week 24 of the first cycle of rituximab treatment, small percentages of patients experienced decreases in IgM (10%), IgG (2.8%), and IgA (0.8%) levels below the lower limit of normal (LLN). When rituximab was administered to RA patients during repeated rituximab treatment, 23.3%, 5.5%, and 0.5% of patients experienced decreases in IgM, IgG, and IgA concentrations below LLN at any time after receiving rituximab, respectively. The clinical consequences of decreases in immunoglobulin levels in RA patients treated with rituximab are not clear at this time. Treatment with rituximab in patients with RA was associated with a decreased level of several biologic markers of inflammation such as interleukin-6 (IL-6), C-reactive protein (CRP), serum amyloid protein (SAA), S100 A8/S100 A9 heterodimer complex (S100 A8/9), anti-citrullinated peptide (anti-CCP), and RF Label and was found to decrease disease symptoms 2.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis In GPA and MPA patients, peripheral blood CD19 B-cells were depleted to less than 10 cells/μl after the first two infusions of rituximab and remained at the same level in most (84%) patients through Month 6 of the treatment. By Month 12, most patients (81%) demonstrated signs of B-cell return with counts >10 cells/μL. By Month 18, the majority of patients (87%) had counts >10 cells/μL Label.
- Mechanism of action
Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
Rituximab belongs to the immunoglobulin G1 (IgG1) sub-class, consisting of a murine variable region (Fab region) and a human constant region (Fc region). The Fab region has variable sections that define a specific target antigen, allowing the antibody to attract and secure its exclusive antigen, specifically the binding of rituximab (IgG1) to CD20 on pre-B and mature B lymphocytes. The Fc region is the tail end of the antibody that communicates with cell surface receptors to activate the immune system, in this case, a sequence of events leading to the depletion of circulating B lymphocytes by complement-dependent cell lysis, antibody-dependent cellular cytotoxicity, as well as apoptosis 6.
In regards to the mechanism of action in rheumatoid arthritis, B cells are thought to play a role in the pathogenesis of rheumatoid arthritis (RA) and the associated condition of chronic synovitis. B cells may act at various sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or the production of proinflammatory cytokines Label. The administration of rituximab in this condition has been shown to result in significant clinical and symptomatic improvements 2, Label.
Target Actions Organism AB-lymphocyte antigen CD20 antibodyHumans - Absorption
Following the administration of 2 doses of rituximab in patients with rheumatoid arthritis (RA), the mean (± S.D.; % CV) concentrations after the first infusion (Cmax first) and second infusion (Cmax second) were : 157 ( ± 46; 29%) and 183 ( ± 55; 30%) mcg/mL, and 318 ( ± 86; 27%) and 381 ( ± 98; 26%) mcg/mL for the 2 × 500 mg and 2 × 1000 mg doses, respectively Label.
- Volume of distribution
3.1 L in Rheumatoid Arthritis Label
4.5 L in Granulomatosis with polyangitis and microscopic polyangitis Label
- Protein binding
- Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system 5.
- Route of elimination
Likely eliminated through the reticuloendothelial system 5.
- Half-life
Non-Hodgkin's Lymphoma: Based on a population pharmacokinetic analysis of data from 298 Non-Hodgkin's Lymphoma (NHL) patients who received rituximab once weekly or once every three weeks, the estimated median terminal elimination half-life was 22 days (range, 6.1 to 52 days) Label.
Rheumatoid Arthritis: Mean terminal elimination half-life was 18.0 days in patients with rheumatoid arthritis Label Based on a population pharmacokinetic analysis of data from 2005 RA patients who received rituximab Label.
Chronic Lymphocytic Leukemia (CLL): Pharmacokinetics were studied in 21 patients with CLL receiving rituximab according to the recommended dose and schedule. The estimated median terminal half-life of rituximab was 32 days (range, 14-62 days) Label.
Granulomatosis with Polyangitis and Microscopic Polyangitis: Based on the population pharmacokinetic analysis of data in 97 GPA and MPA patients who received 375 mg/m2 rituximab once weekly by intravenous infusion for four weeks, the estimated median terminal elimination half-life was 23 days (range, 9 to 49 days) Label.
- Clearance
Rheumatoid Arthritis: 0.335 L/day Label
Granulomatosis with Polyangitis and Microscopic Polyangitis: 0. 312 L/day Label
Patients with higher CD19-positive cell counts or larger measurable tumor lesions at pretreatment had a higher clearance Label.
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
Oral LD50: 27 mg/kg (mouse and rat) MSDS
Inhalation LD50: 32 mg/m3 (mouse) and 37 mg/m3 (rat) MSDS
Skin LD50: 20 mg/kg (rabbit) and 50 mg/kg (rat) MSDS
Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to establish the carcinogenic or mutagenic potential of rituximab or to determine potential effects on fertility in males or females Label.
Embryo-Fetal toxicity: Can cause neonatal harm. Advise of potential risk to neonates and use of effective contraception Label.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A (G;G) / (G;T) T > G Effect Directly Studied Patients with this genotype have increased frequency of anti-tumor response when using rituximab to treat diffuse large B-cell lymphoma, follicular lymphoma, or [follicular non-Hodgkin lymphoma]. Details
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept Rituximab may increase the immunosuppressive activities of Abatacept. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Rituximab. Acebutolol Acebutolol may increase the hypotensive activities of Rituximab. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Rituximab. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Rituximab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rituximab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rituximab. Alefacept The risk or severity of adverse effects can be increased when Rituximab is combined with Alefacept. Alemtuzumab The risk or severity of adverse effects can be increased when Rituximab is combined with Alemtuzumab. Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- No interactions found.
Products
- Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
- International/Other Brands
- MabThera (Roche) / Riabni
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Blitzima Injection, solution, concentrate 100 mg Intravenous Celltrion Healthcare Hungary Kft. 2020-11-24 Not applicable EU Blitzima Injection, solution, concentrate 500 mg Intravenous Celltrion Healthcare Hungary Kft. 2020-11-24 Not applicable EU Mabthera Injection, solution 1600 mg Subcutaneous Roche Registration Gmb H 2021-02-11 Not applicable EU Mabthera Injection, solution, concentrate 100 mg Intravenous Roche Registration Gmb H 2021-02-11 Not applicable EU Mabthera Injection, solution 1400 mg Subcutaneous Roche Registration Gmb H 2021-02-11 Not applicable EU Mabthera Injection, solution, concentrate 500 mg Intravenous Roche Registration Gmb H 2021-02-11 Not applicable EU Riabni Injection, solution 500 mg/50mL Intravenous AMGEN INC 2021-01-06 Not applicable US Riabni Injection, solution 100 mg/10mL Intravenous AMGEN INC 2021-01-06 Not applicable US Ritemvia Injection, solution, concentrate 100 mg Intravenous Celltrion Healthcare Hungary Kft. 2020-12-16 Not applicable EU Ritemvia Injection, solution, concentrate 500 mg Intravenous Celltrion Healthcare Hungary Kft. 2020-12-16 Not applicable EU - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Rituxan Hycela Rituximab (120 mg/1mL) + Hyaluronidase (human recombinant) (2000 U/1mL) Injection, solution Subcutaneous Genentech, Inc. 2017-06-22 Not applicable US Rituxan Hycela Rituximab (120 mg/1mL) + Hyaluronidase (human recombinant) (2000 U/1mL) Injection, solution Subcutaneous Genentech, Inc. 2017-06-22 Not applicable US
Categories
- ATC Codes
- L01XC02 — Rituximab
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Antirheumatic Agents
- Biologics for Rheumatoid Arthritis Treatment
- Blood Proteins
- Cancer immunotherapy
- CD20-directed Antibody Interactions
- CD20-directed Cytolytic Antibody
- Globulins
- Immunoglobulins
- Immunologic Factors
- Immunoproteins
- Immunosuppressive Agents
- Immunotherapy
- Myelosuppressive Agents
- Narrow Therapeutic Index Drugs
- Proteins
- Serum Globulins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 4F4X42SYQ6
- CAS number
- 174722-31-7
References
- General References
- McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. [PubMed:9704735]
- Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. [PubMed:15201414]
- Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. [PubMed:15795920]
- Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. [PubMed:16705086]
- Ryman JT, Meibohm B: Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. doi: 10.1002/psp4.12224. Epub 2017 Jul 29. [PubMed:28653357]
- Emer JJ, Claire W: Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2009 May;2(5):29-37. [PubMed:20729962]
- FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma [Link]
- FDA Approves Two New Indications for Rituxan in Patients With Non-Hodgkin's Lymphoma [Link]
- FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels [Link]
- External Links
- UniProt
- P01857
- Genbank
- J00228
- PubChem Substance
- 46505820
- 121191
- ChEMBL
- CHEMBL1201576
- Therapeutic Targets Database
- DAP000382
- PharmGKB
- PA451261
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Rituximab
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- FDA label
- Download (257 KB)
- MSDS
- Download (117 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Transplant, Kidney 1 4 Active Not Recruiting Treatment Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis 1 4 Active Not Recruiting Treatment Function of Renal Transplant 1 4 Completed Other Autoimmune Diseases / Transplant, Kidney 1 4 Completed Prevention Autoimmune Adrenocortical Failure 1 4 Completed Prevention Transplantation, Kidney 1 4 Completed Treatment Acute Lymphoblastic Leukaemias (ALL) 1 4 Completed Treatment Adult Acute Lymphocytic Leukemia 1 4 Completed Treatment Burkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms 1 4 Completed Treatment Chronic Lymphocytic Leukaemia (CLL) 1
Pharmacoeconomics
- Manufacturers
- Roche
- Packagers
- Biogen Idec Inc.
- F Hoffmann-La Roche Ltd.
- Genentech Inc.
- Dosage Forms
Form Route Strength Injection, solution, concentrate Intravenous 100 mg Injection, solution, concentrate Intravenous 500 mg Solution, concentrate Intravenous 500 mg Solution Intravenous 100 mg Injection Intravenous 10 MG/ML Injection Intravenous 1400 MG/11.7ML Injection, solution Subcutaneous 1600 mg Injection, solution, concentrate Intravenous Solution Solution Intravenous 500 mg Injection Intravenous 100 mg Injection, solution, concentrate Intravenous 100 MG/10ML Injection, solution Intravenous 120 mg/mL Injection, solution Subcutaneous 1400 MG Injection Intravenous 500 mg/50ml Injection, solution, concentrate Intravenous 500 MG/50ML Solution Intravenous 10 mg Solution, concentrate Intravenous 10 mg/ml Solution Subcutaneous 1400 mg Solution Intravenous 100 mg/10ml Solution Intravenous 500 mg/50ml Injection, solution Intravenous 10 mg/1mL Injection, solution Subcutaneous Solution Subcutaneous Solution, concentrate Intravenous 10 mg Solution Intravenous Injection, solution Intravenous 100 mg/10mL Injection, solution Intravenous 500 mg/50mL Injection, solution Intravenous Injection, solution, concentrate Intravenous; Parenteral 100 MG Injection, solution, concentrate Intravenous; Parenteral 500 MG Injection, solution - Prices
Unit description Cost Unit Rituxan 10 mg/ml Concentrate 10ml Vial 708.17USD vial Rituxan 10 mg/ml vial 68.09USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2149329 No 2008-07-15 2013-11-12 Canada CA1336826 No 1995-08-29 2012-08-29 Canada US5736137 No 1998-04-07 2015-04-07 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment) http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062 hydrophobicity -0.414 http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062 isoelectric point 8.68 http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062
Targets

- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antibody
- General Function
- Mhc class ii protein complex binding
- Specific Function
- This protein may be involved in the regulation of B-cell activation and proliferation.
- Gene Name
- MS4A1
- Uniprot ID
- P11836
- Uniprot Name
- B-lymphocyte antigen CD20
- Molecular Weight
- 33076.99 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- van Meerten T, Hagenbeek A: CD20-targeted therapy: the next generation of antibodies. Semin Hematol. 2010 Apr;47(2):199-210. doi: 10.1053/j.seminhematol.2010.01.007. [PubMed:20350667]
- Jaglowski SM, Byrd JC: Rituximab in chronic lymphocytic leukemia. Semin Hematol. 2010 Apr;47(2):156-69. doi: 10.1053/j.seminhematol.2010.01.005. [PubMed:20350663]
- McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. [PubMed:9704735]
- Rituxan FDA label [File]
Drug created on June 13, 2005 13:24 / Updated on February 24, 2021 19:34